

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
INITIATION OF PHASE I/II CLINICAL TRIAL AND COMPLETION OF
FIRST PATIENT ENROLLMENT FOR PCV24

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

The Company is pleased to announce that the Phase I/II clinical trial for the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) (the “**PCV24**”) developed by the Company was officially initiated recently and the first trial patient case has been formally enrolled.

The Company’s PCV24 obtained clinical trial approval granted by the National Medical Products Administration (the “**NMPA**”) of China in January 2026. The Company’s PCV24 covers the major prevalent pneumococcal serotypes currently in circulation. It adopts covalent conjugation method of polysaccharide antigens to protein carriers and a dual carrier technology. The vaccine is intended for vaccination in individuals aged 2 months (minimum 6 weeks) and above to prevent infectious diseases caused by 24 pneumococcal serotypes.

The Company’s 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) (trade name: iPneucia®) obtained the new drug application approval granted by the NMPA in June 2025. PCV24 represents a further expansion of the Company’s pneumococcal vaccine product portfolio. As of the date of this announcement, no 24-valent pneumococcal polysaccharide conjugate vaccine is currently available on the global market.

The Phase I/II clinical trial is designed to evaluate the safety and immunogenicity of PCV24 in subjects aged 2 months (minimum 6 weeks) and above.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, May 25, 2026

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Yiu Leung Andy CHEUNG, Mr. Man CHO and Ms. Xuefeng JI as independent non-executive Directors.